Message from Susan B. Shurin, M.D., Acting Director, NHLBI

November 10, 2010

PA-star: The NHLBI's Special Funding Strategy for Three NIH Funding Opportunity Announcements (FOAs)

Dear Colleagues:

The NHLBI will use a special funding strategy for three Program Announcements (PAs) recently published in the NIH Guide (listed below).

Unamended new (Type 1) applications submitted in response to these PAs will be considered for funding at 5 percentile points above the Institute's regular payline for unamended R01 applications.

Early stage investigators (ESIs) will receive the normal 5 percentile advantage, and will automatically receive an additional 5 percentile advantage without having to resolve comments in the summary statement, for a total of a 10 percentile advantage.

Please follow these links to view the three PAs:

• PA-11-011: Getting from Genes to Function in Lung Disease (R01)
• PA-11-012: Toward An Improved Understanding of HDL Function (R01)
• PA-11-013: Sickle Cell Disease: Inflammation, Thrombosis and Vascular Dysfunction (R01)

This policy has also been posted to http://www.nhlbi.nih.gov/funding/inits/index.htm#pa

With best wishes,
Susan B. Shurin

An Archive of the current and past issues is available on the NHLBI Web site.